Skip to main content

Table 1 Basic information of the patients

From: HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

Characteristic

HIFU (N = 8)

BSC (N = 16)

PC (N = 16)

p value

Age (years), Median (IQR)

61.5 (58.2–65.3)

63.2 (59.4–65.5)

62.5 (58.1–66.3)

 > 0.1

Gender

 > 0.1

 Male

6

8

6

 

 Female

2

8

10

 

BMI(kg/m2), Median (IQR)

20.5 (18.1–22.5)

19.5 (17.8–21.8)

20.0 (19.2–23.0)

 > 0.1

Comorbidity

 > 0.1

 No

2

7

8

 

 Yes

6

9

8

 

ECOG performance status

 > 0.1

 0

4

4

6

 

 1

4

10

9

 

 2

0

2

1

 

Child–Pugh class

 > 0.1

 Grade A

7

13

11

 

 Grade B

1

3

5

 

Liver metastases

 > 0.1

 Synchronous

2

1

1

 

 Metachronous

6

15

15

 

First-line treatment of liver metastases

NA

 Chemotherapy

2

–

16

 

 RFA

2

–

0

 

 HIFU + TACE

2

–

0

 

 HIFU

2

–

0

 

Chemotherapy before surgery

0.09

 No

6

16

15

 

 Yes

2

0

1

 

TNM stage of GC

 > 0.1

 I

1

4

2

 

 II

1

3

4

 

 III

4

8

9

 

 IV

2

1

1

 

Number of lymph nodes retrieved, Median (IQR)

19 (12–26)

18 (12–27)

20 (13–25)

 > 0.1

  1. HIFU high intensity focused ultrasound, BSC best supportive care, PC palliative chemotherapy, BMI body mass index, ECOG Eastern Cooperative Oncology Group, RFA radiofrequency ablation, TACE transcatheter arterial chemoembolization, GC gastric cancer, NA not available